What stands out
- Semaglutide and tirzepatide options
- Advertises included supplies and shipping
What to weigh
- Compounded medications are not FDA-approved.
- Provider performance is not established by branded-drug trial results.
Two ingredients within one provider
CoreAge Rx advertises compounded semaglutide and compounded tirzepatide, with clinician review before prescribing. That makes the provider relevant to readers comparing access to both ingredients, but it does not make the two preparations equivalent or guarantee eligibility.[source]
The important first distinction is finished-product status. These are provider-described compounded medicines, not branded Wegovy and Zepbound. Their ingredient names should not erase that difference.
What the starting prices establish
The publisher supplied corrected CoreAge Rx starting prices of $79 per month for semaglutide and $129 per month for tirzepatide, with a same-price-at-every-dose claim. Those are provider offers, not independently tested total-cost guarantees.[source]
Confirm the selected billing term, initial charge, included follow-up, shipping and any applicable consultation fee. The help catalog describes multi-month arrangements and a consultation-fee deduction if no prescription is issued.[source]
Keep the trial separate from the service
SURMOUNT-5 compared specified doses of branded weekly injections in a randomized study. It did not test CoreAge Rx, its pharmacies or its compounded products. Quoting the trial’s mean weight loss as a predicted provider result would overstate the evidence.[source]
FDA explains that unapproved GLP-1 products do not undergo the same review as approved finished drugs and raises concerns including dosing errors and semaglutide salt forms. Ask what is being dispensed and why that preparation is proposed.[source]
Clinical follow-up matters to the comparison
Ask who answers medication questions, how adverse effects are reviewed and which pharmacy fills the prescription. A generic promise of online access does not establish a measured clinical response time; we did not enroll to test the service.
Discuss medical history, current medicines and prior treatment with the clinician. This publication cannot decide which ingredient, formulation or dose fits an individual.
Why the provider appears first
CoreAge Rx is the featured commercial partner. Its placement does not establish superior efficacy, lowest complete cost or equivalence to an approved product. The two separate product reviews explain the semaglutide and tirzepatide offers in more detail.
Readers considering branded medicine should also examine Ro, Hers and LillyDirect. Comparing access models is useful only when the underlying products remain clearly identified.
Two more care models to compare
OrderlyMeds adds entry and transfer packages for both compounded ingredients; WeightWatchers adds an approved-medication care membership with separate drug costs. Neither can be compared fairly with CoreAge Rx using one headline number alone. Match the actual preparation, time period, included care and renewal terms.
The new outcomes guide also explains why member statistics do not settle a tirzepatide-versus-semaglutide decision. CoreAge Rx remains featured through commercial placement. The choice of medicine and the rationale for a compounded product remain clinical questions.[source]
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- CoreAge Rx: current advertised treatments and pricesStandard GLP-1 prices use the publisher-supplied correction: semaglutide $79/month from; tirzepatide $129/month from. Other original service details retain their October 8 check date. · Checked October 8, 2026
- CoreAge Rx Help Center: current product catalogProvider formulation and consultation information · Checked October 8, 2026
- Aronne et al., NEJM 2025: tirzepatide compared with semaglutide for obesityPrimary randomized trial abstract; SURMOUNT-5, 751 adults without diabetes, 72 weeks; funded by Eli Lilly · Checked October 8, 2026
- FDA: concerns with unapproved GLP-1 drugsCompounded-product risks, salt forms, dosing errors and online red flags · Checked October 10, 2026